

# PUBLIC HEALTH WEBINAR SERIES ON BLOOD DISORDERS

BRINGING SCIENCE INTO PRACTICE

The Division of Blood Disorders is proud to offer this webinar series, providing evidence-based information on new research, emerging issues of interest in blood disorders, as well as innovative approaches to collaboration.

## KEY FINDINGS FROM RECENT INVESTIGATOR-INITIATED MULTICENTER TRIALS IN PEDIATRIC VENOUS THROMBOEMBOLISM TREATMENT AND PREVENTION: KIDS-DOTT (DURATION OF THERAPY FOR THROMBOSIS) AND COVAC-TP (COVID-19 ANTICOAGULATION IN CHILDREN - THROMBOPROPHYLAXIS)


MARCH 23, 2023 • 2:00–3:00 PM ET



**Neil A. Goldenberg, MD, PhD**  
Global Principal Investigator, Kids-DOTT Trial  
Associate Dean for Research,  
Johns Hopkins All Children's Hospital  
Director, Johns Hopkins All Children's Institute  
for Clinical & Translational Research,  
Johns Hopkins All Children's Hospital



**Anthony A. Sochet, MD, MHS**  
National Principal Investigator, COVAC-TP Trial  
Assistant Professor of Anesthesiology and  
Critical Care Medicine, Johns Hopkins  
University School of Medicine  
Associate Director, Pediatric Critical Care  
Medicine Fellowship Program,  
Johns Hopkins All Children's Hospital



**Julie Jaffray, MD (MODERATOR)**  
Pediatric Hematologist/Oncologist,  
Rady Children's Hospital San Diego  
Clinical Assistant Professor, Department of Pediatrics,  
UC San Diego

Venous thromboembolism (VTE) is increasingly being diagnosed in pediatric patients. While an increase may in part be explained by improved identification, VTE has become one of the most common complications of hospitalization in children. Furthermore, the consequences of VTE in childhood can be felt lifelong. Therefore, improving knowledge on pediatric VTE treatment and prevention is a public health priority that should engage patients, parents, pediatric and adult primary care providers, and subspecialists.

In this webinar, Drs. Goldenberg and Sochet will discuss key aspects of VTE in children, including incidence, risk factors, and outcomes, as well as critical knowledge gaps in optimal treatment and prevention. They will then summarize the design and findings of two recently published investigator-initiated clinical trials of VTE treatment (Kids-DOTT phase 3 multinational trial on duration of anticoagulation in patients younger than 21 years old with provoked VTE) and prevention (COVAC-TP, U.S. national phase 2 on pharmacological thromboprophylaxis in children hospitalized for COVID-19-related illness, including multisystem inflammatory syndrome in children). Lastly, they will outline key questions for future research.

### LEARNING OBJECTIVES:

1. Describe the incidence, risk factors, and outcomes of VTE in children.
2. Identify historical knowledge gaps in pediatric VTE treatment and prevention.
3. Describe the latest evidence on the optimal duration of anticoagulation for the treatment of provoked VTE in patients younger than 21 years of age.
4. Describe the safety of enoxaparin thromboprophylaxis in children hospitalized for COVID-19.

This webinar is free and open to healthcare providers, pharmacists, and public health researchers who desire more information about venous thromboembolism.

**PLEASE PREREGISTER HERE:** <https://bit.ly/CDCMarch23>

**For more information please contact Cynthia Sayers:** [cay1@cdc.gov](mailto:cay1@cdc.gov)